About U7 snRNA-associated Sm-like protein LSm11
U7 snRNA-associated Sm-like protein LSm11 (LSM11) is a protein
from Homo sapiens identified by UniProt accession
P83369, 360 residues long.
MolForge cross-references it against 0 known binders and
45 disease associations.
Target properties
| Protein name | U7 snRNA-associated Sm-like protein LSm11 |
| UniProt accession | P83369 |
| Gene | LSM11 |
| Organism | Homo sapiens |
| Length | 360 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (45)
Diseases linked to this target (Open Targets).
- neurodegenerative disease · score 0.53
- Aicardi-Goutieres syndrome 8 · score 0.45
- Aicardi-Goutières syndrome · score 0.37
- mean corpuscular volume · score 0.30
- Red cell distribution width · score 0.27
- mean reticulocyte volume · score 0.25
- mean corpuscular hemoglobin concentration · score 0.11
- hair shape measurement · score 0.09
- diastolic blood pressure · score 0.08
- systolic blood pressure · score 0.08
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-P83369-F1 | alphafold | PREDICTED | 64.29 | — |
Amino-acid sequence (360 residues)
MEERERGARS AGAGSPARPP SPRLDVSSDS FDPLLALYAP RLPPIPYPNA PCFNNVAEYE SFLRTGVRGG GRGRGRARGA AAGSGVPAAP GPSGRTRRRP DAPAPDPERI QRLRRLMVAK EEGDGAAGAG RRGPGRSRKA PRNVLTRMPL HEGSPLGELH RCIREGVKVN VHIRTFKGLR GVCTGFLVAF DKFWNMALTD VDETYRKPVL GKAYERDSSL TLTRLFDRLK LQDSSKKEAD SKSAVEDSTL SRYSQTSTWK LASVWGRADT GRGSHKRSRS VPSSLQASAR EESRSELSGR TTRTDGSSVG GTFSRATTLS RGQSRKKKRK PKVDYQQVFT RHINQIFIRG ENVLLVHLAQ
Explore U7 snRNA-associated Sm-like protein LSm11 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets